NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 795)
Posted On: 01/29/2018 5:27:22 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to the 60-90 minutes required for current methods, and is already in use in a number of consumer products. The technology is already attracting the attention of Big Pharma, and Lexaria is in negotiations with major pharmaceutical companies to license its technology.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to the 60-90 minutes required for current methods, and is already in use in a number of consumer products. The technology is already attracting the attention of Big Pharma, and Lexaria is in negotiations with major pharmaceutical companies to license its technology.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼